A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Overall Design: a multicenter, randomized, double-blind, placebo-controlled, parallel-group,
dose-exploration study.
Main outcome: 1.To evaluate the efficacy and safety of XY03-EA tablets in the treatment of
acute ischemic stroke.